STARD4 and hepatocellular carcinoma: Consistent with the above results, overexpression of STARD4 increased protein levels of p-EGFR, p-PI3K, and p-AKT in HCC cells, while erlotinib inhibited this STARD4-induced activation of EGFR/PI3K/AKT signaling pathway.